Company Announcement, Helsinki, 5 December 2024 at 10 AM (EET)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announced on 29 November 2024 that the Board of Directors of the Company has decided to issue 250,000 new shares ("New Shares") to Brainlab AG by way of a directed share issue and Brainlab AG has subscribed for all shares issued in the directed share issue. It was also announced that a total of 146,194 new shares in the Company were subscribed on 29 November 2024 with a convertible bond previously issued by the Company (the "Convertible Bond").
The New Shares and the Company's shares subscribed with the Convertible Bond have been registered with the Finnish Trade Register on 4 December 2024. Following the registration, the total number of shares in the Company amounts to 7,161,756 shares. The New Shares and the Company's shares subscribed with the Convertible Bond will confer shareholder rights once they have been registered with the Finnish Trade Register and entered in the book-entry accounts.
The New Shares and the Company's shares subscribed with the Convertible Bond will be traded on Nasdaq First North Growth Market Finland, maintained by Nasdaq Helsinki Ltd, with the Company’s old shares starting on or about 5 December 2024.
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.
In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com